Novocure outlines 2026 revenue of $710M-$725M while targeting adjusted EBITDA of $0M-$15M (NASDAQ:NVCR)

Novocure provided 2026 guidance showing revenue of $710M–$725M paired with adjusted EBITDA targets of $0M–$15M, signaling a transition toward sustained profitability. The midpoint implies low-single-digit growth, reflecting cautious demand assumptions in the oncology device sector despite recent product developments.

The company is pursuing $90M in cost reductions, a material efficiency initiative that underpins the EBITDA improvement trajectory. This operational discipline addresses investor concerns about scale and margin sustainability in a competitive neurooncology market. Updates on Optune Pax and Lua product lines suggest pipeline maturation, though revenue guidance conservatism indicates execution risk remains priced in.

The guidance range is notably wide on EBITDA (0–15M), implying management uncertainty around either revenue realization or cost control timing. This volatility band may limit institutional confidence, despite the positive directional bias on profitability inflection.

Sector implication: Health Care device innovators are under pressure to demonstrate operating leverage and path to cash generation. NVCR's guidance reflects sector-wide scrutiny of biotech/medtech burn rates and reimbursement headwinds, positioning disciplined capital allocation as a relative strength indicator.